



UWL REPOSITORY

repository.uwl.ac.uk

Intestinal protozoan and helminthic infections among hemodialysis and cancer patients

Mahmoudi, Mohammad Reza, Hasani, Hoseyin, Tsiami, Amalia ORCID logo ORCID: <https://orcid.org/0000-0002-1122-4814>, Ashrafi, Keyhan, Johnson, Paul, Sharifdini, Mysam and Karanis, Panagiotis (2020) Intestinal protozoan and helminthic infections among hemodialysis and cancer patients. Parasitology Research. ISSN 0932-0113

<http://dx.doi.org/10.1007/s00436-020-06774-5>

This is the Accepted Version of the final output.

UWL repository link: <https://repository.uwl.ac.uk/id/eprint/7042/>

Alternative formats: If you require this document in an alternative format, please contact: open.research@uwl.ac.uk

Copyright:

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy: If you believe that this document breaches copyright, please contact us at open.research@uwl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Rights Retention Statement:

Parasitology Research

Intestinal protozoan and helminthic infections among hemodialysis and cancer patients

--Manuscript Draft--

Manuscript Number:	
Full Title:	Intestinal protozoan and helminthic infections among hemodialysis and cancer patients
Article Type:	Original Paper
Section/Category:	Treatment and Prophylaxis
Funding Information:	
Abstract:	<p>Intestinal parasitic infections (IPIs) can be a severe threat to immunocompromised patients. This is particularly true for those undergoing chemotherapy and hemodialysis. The present research is aimed at identifying intestinal parasites that might be present in immunocompromised patients. In this cross-sectional study 1040 stool samples were collected (279 samples from hemodialysis patients, 362 samples from chemotherapy patients and 399 samples from the control group) from March to September 2017. The samples were tested by direct, formalin-ether methods for protozoa and ova of intestinal parasites and Ziehl-Neelsen staining methods for coccidian parasites such as <i>Cryptosporidium</i> species. The overall parasitic infection rate was higher (15%) in hemodialysis patients and 11.3% in chemotherapy patients whereas the lowest rate was observed (7.3%) in the control group. The infectivity rates were statistically significant ($P = 0.008$) when compared with the control group. The most prevalent parasites present were <i>Blastocystis hominis</i> (8.9% of the cases), <i>Entamoeba coli</i> (1.6%), <i>Iodamoeba butschlii</i> (0.8%), <i>Endolimax nana</i> (0.6%), <i>Chilomastix mesnili</i> (0.5%), <i>Strongyloides stercoralis</i> (0.5%) and <i>Taenia</i> species (0.15%), whereas <i>Giardia lamblia</i> was found present only in the control group. Statistical analyses revealed a significant correlation between gastrointestinal symptoms (such as some abdominal pain, diarrhea) and the ratio of chemotherapy frequency to scheduled frequency and parasitic infections ($P = 0.001$). There was not a correlation between prevalence of parasites with age or education levels of the infected individuals. Results of the present study suggest that a periodic stool examinations in special parasitological laboratories should be included as part of routine and general medical care.</p>
Corresponding Author:	Panagiotis Karanis, Ph.D University of Nicosia Medical School Nicosia, CYPRUS
Corresponding Author Secondary Information:	
Corresponding Author's Institution:	University of Nicosia Medical School
Corresponding Author's Secondary Institution:	
Order of Authors:	<p>Mohammad Reza Mahmoudi</p> <p>Hoseyin Hasani</p> <p>Amalia Tsiami</p> <p>Keyhan Ashrafi</p> <p>Paul Johnson</p> <p>Mysam Sharifdini</p> <p>Panagiotis Karanis, Ph.D</p>
First Author:	Mohammad Reza Mahmoudi
First Author Secondary Information:	
Order of Authors Secondary Information:	

Author Comments:	
Suggested Reviewers:	Matthew E Falagas m.falagas@aibs.gr Expert in the field with original reviews
	Debby Keller debby_keller@hotmail.com Expert in the field of Cancer
	U Navaneethan udhaykumar81@gmail.com Expert in clinical cancer research
	Żaneta Kopacz zaneta.kopacz@umed.wroc.pl Expert in the field; published on parasites and carcinoma

[Click here to view linked References](#)

1
2
3
4 **Intestinal protozoan and helminthic infections among hemodialysis and cancer patients**
5
6
7

8
9 **Mohammad Reza Mahmoudi^{1,2,3}, Hoseyin Hasani¹, Amalia Tsiami⁴, Keyhan Ashrafi¹, Paul**
10 **Johnson⁶, Mysam Sharifdini¹, Panagiotis Karanis^{5,6*}**
11
12
13
14

15
16
17 1-Department of Medical Parasitology and Mycology, School of Medicine, Guilan University of
18
19 Medical Sciences, Rasht, Iran
20

21 2- Cellular and Molecular Research Center, School of Medicine, Guilan University of Medical
22
23 Sciences, Rasht, Iran.
24

25
26 3-Medical Biotechnology Research Center, School of Paramedicine, Guilan University of Medical
27
28 Sciences, Rasht, Iran.
29

30
31 4-Associate Professor in Food Science and Nutrition, London Geller College of Hospitality and
32
33 Tourism University of West London | St. Mary's Road, Ealing, London W5 5RF, United Kingdom
34
35 Direct
36
37

38 5-University of Cologne, Faculty of Medicine and University Hospital, Cologne, Germany.
39

40
41 6-University of Nicosia Medical School, Department of Basic and Clinical Sciences, Nicosia,
42
43 Cyprus.
44

45
46
47
48 ***Corresponding Author: Prof. P. Karanis (karanis@unic.ac.cy)**
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 **ABSTRACT**
5

6 Intestinal parasitic infections (IPIs) can be a severe threat to immunocompromised patients. This
7 is particularly true for those undergoing chemotherapy and hemodialysis. The present research is
8 aimed at identifying intestinal parasites that might be present in immunocompromised patients. In
9 this cross-sectional study 1040 stool samples were collected (279 samples from hemodialysis
10 patients, 362 samples from chemotherapy patients and 399 samples from the control group) from
11 March to September 2017. The samples were tested by direct, formalin-ether methods for protozoa
12 and ova of intestinal parasites and Ziehl-Neelsen staining methods for coccidian parasites such as
13 *Cryptosporidium* species. The overall parasitic infection rate was higher (15%) in hemodialysis
14 patients and 11.3% in chemotherapy patients whereas the lowest rate was observed (7.3%) in the
15 control group. The infectivity rates were statistically significant ($P = 0.008$) when compared with
16 the control group. The most prevalent parasites present were *Blastocystis hominis* (8.9% of the
17 cases), *Entamoeba coli* (1.6%), *Iodamoeba butschlii* (0.8%), *Endolimax nana* (0.6%), *Chilomastix*
18 *mesnili* (0.5%), *Strongyloides stercoralis* (0.5%) and *Taenia* species (0.15%), whereas *Giardia*
19 *lamblia* was found present only in the control group. Statistical analyses revealed a significant
20 correlation between gastrointestinal symptoms (such as some abdominal pain, diarrhea) and the
21 ratio of chemotherapy frequency to scheduled frequency and parasitic infections ($P = 0.001$). There
22 was not a correlation between prevalence of parasites with age or education levels of the infected
23 individuals. Results of the present study suggest that a periodic stool examinations in special
24 parasitological laboratories should be included as part of routine and general medical care.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Keywords: Parasites, dialysis, chemotherapy, prevalence

1
2
3
4 **Introduction**
5
6
7
8

9 Intestinal parasitic infestations cause a variety of clinical conditions, the majority of which are
10 related to the gastrointestinal (GI) tract. Intestinal parasites are among the most common human
11 infections distributed worldwide (Bora 2016). One fourth of all known diseases are caused by
12 parasites (Cleaveland Laurenson and Taylor 2001).
13
14
15
16
17

18 There is evidence that some parasitic infections are associated with cancer development. The level
19 of evidence of this association varies from high to low; in any case, a long time interval is
20 mandatory for the development of cancer. *Opisthorchis viverrini* and *Clonorchis sinensis* are
21 associated with cholangiocarcinoma, *Schistosoma hematobium* with bladder cancer (Samaras et
22 al. 2010). According to the World Health Organisation (2019) certain viruses, bacteria, and
23 parasites can act as biological carcinogens. It is suggested that in low- and middle-income
24 countries as many as 15% of cancers diagnosed in 2012 could be attributed to carcinogenic
25 infections; Martel et al. (2020) estimated for 2018, around 2.2 million infection-attributable
26 cancers were diagnosed worldwide. According to Cancer Research UK (2020) bile duct cancer
27 and bladder cancer can be directly attributed to parasites.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

43 Changes in social and cultural context have influenced the human-parasite relations during the past
44 century. Currently, parasitic diseases are more prevalent in underdeveloped countries (Bloom and
45 Murray 1992). Patients undergoing chemotherapy or hemodialysis are considered to be
46 immunocompromised and specific steps in healthcare are followed to reduce the risk of infection
47 (Ferreira and Borges 2002). It has been observed that healthy individuals could also be affected by
48 intestinal parasites. They often express self-limiting symptoms, but they can increase the risk of
49 infecting immunocompromised individuals (Bora 2016).
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 Infections increase the mortality rates and it is considered as the second highest cause of mortality
5
6 for hemodialysis patients (Tonelli et al. 2006). There is also evidence that there is a high rate of
7
8 parasitic infections in cancer patients, especially those that undergo chemotherapy (Zabolinejad et
9
10 al. 2013; Barazesh et al. 2015). Directing the awareness of physicians towards the early diagnosis,
11
12 and rapid and proper treatment of such pathogens could reduce the morbidity and mortality rate as
13
14 well as reducing the medical costs.
15
16

17
18 The present study was conducted to investigate the prevalence of IPIs in two groups of patients
19
20 (hemodialysis patients and chemotherapy patients), compared with the control (patients not
21
22 diagnosed with those conditions) group.
23
24
25
26
27

28 **Material and Methods**

29 *2.1. Ethics statement*

30
31
32
33
34
35
36 The cross-sectional study was approved by the Ethics Committee of Guilan University of Medical
37
38 Sciences with ethics number of IR.GUMS.REC.1396.141.
39
40

41 *2.2. Study area and sample collection*

42
43
44 The patients who were eligible for the study, were informed about the research plan and their
45
46 consent was taken before recruitment. Participants were referred from Razi Hospital, Guilan
47
48 Oncology Center, Kianmehr Hemodialysis Center, and Caspian Hemodialysis Center in Rasht,
49
50 Guilan province. During this period, fresh stool samples were collected from 362 cancer patients,
51
52 279 hemodialysis patients and 399 individuals (control group) who were without any signs and
53
54 symptoms of malignancy. During the first stage, demographic data were collected (age, gender,
55
56 residence and education). Further self-reported information about their health was obtained. For
57
58
59
60
61
62
63
64
65

1
2
3
4 the participants with cancer, the type of cancer, number of completed chemotherapy sessions
5
6 undergone, the date of the first chemotherapy session was recorded. For the hemodialysis patients,
7
8 the following parameters were self-reported: the number of sessions, the date of their first dialysis
9
10 and the frequency of treatment was recorded. Participants that took anti-parasitic drugs, antibiotics,
11
12 mineral oils, barium, bismuth and non-absorbable anti-diarrhea drugs two weeks prior were
13
14 excluded from the study. The inclusion criteria for the control group were:
15
16
17

- 18 1. Patients without chronic infections
- 19 2. Cancer patients receiving at least one course of chemotherapy
- 20 3. Hemodialysis patients at least three months post their first dialysis were included in the
21 study.
22
23
24
25
26
27
28
29
30
31

32 *2.3. Stool sample examination*

33
34
35
36
37 Fecal samples were collected in specimen containers from each individual and were transferred to
38
39 the Department of Parasitology, School of Medicine, Guilan University of Medical Sciences.
40
41 Macroscopic investigation of stool samples was performed to detect mucus and blood. The
42
43 microscopic screening included direct wet smear (saline preparation and iodine preparation) and
44
45 formalin-ether concentration to detect intestinal amoeba and flagellate (Bora et al.2016; Garcia
46
47 2007). The oocysts of coccidian parasites (*Cryptosporidium* spp., *Isospora belli*), were examined
48
49 with a modified acid-fast technique using light microscopy with a magnification of 100× according
50
51 to Garcia et al. (1983).
52
53
54
55
56
57
58

59 *2.4. Statistical analysis*

60
61
62
63
64
65

1
2
3
4
5
6
7 The data were statistically analyzed using SPSS software (SPSS version 16). Differences between
8
9 variable groups were analyzed by Chi-Squared test, and test significance level was $p < 0.05$.
10
11
12

13 14 **3. Results**

15
16
17
18
19 This study compares the prevalence of intestinal parasites between 641 immunocompromised
20
21 patients (including 362 chemotherapy and 279 hemodialysis patients), and 399 'healthy' subjects
22
23 as defined above. 49.9% of the participants were female and 50.1% male and their age range was
24
25 60-79 years old (Table 1). For all groups the infection rates 13% (see Table 1). The IPI rates for
26
27 the individual groups were 11.3%, 15% and 7.3% for chemotherapy patients, hemodialysis patients
28
29 and the control group, respectively. The IPI rates were significantly different between the three
30
31 groups ($P = 0.008$). *Blastocystis hominis* was the most prevalent (8.9%) parasite observed in
32
33 patients followed by *Entamoeba coli* (1.6%), *Iodamoeba butschlii* (0.8%), *Endolimax nana*
34
35 (0.6%), *Chilomastix mesnili* (0.5%), *Strongyloides stercoralis* (0.5%) and *Taenia* species (0.15%).
36
37 In the present study, helminthes, namely *S. stercoralis* and *Taenia* species were the only
38
39 pathogenic parasites detected in the patients. Similar to the patients, *B. hominis* was the most
40
41 prevalent (8.9%) parasite observed in the control group, followed by *G. lamblia* (2%), *I. butschlii*
42
43 (0.5%), *E. coli* (0.25%), *E. nana* (0.25%), and *C. mesnili* (0.25%). The pathogenic protozoa, *G.*
44
45 *lamblia*, was the only pathogenic parasite detected in the 'control group (Table 2). Multiple
46
47 infections were detected in five participants (four in the hemodialysis and one in the cancer group).
48
49 In all multiple infection cases, *B. hominis* was a constant finding. The association among the
50
51 prevalence of IPIs, demographics (age, gender, education, residence) and clinical symptoms is
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 presented in Table 3. The rate of IPI was significantly higher in rural, compared with urban
5 residence ($P = 0.001$). However, demographic characteristics were not associated with the
6 prevalence of IPIs (see Table 3). For the hemodialysis group it appears that there is no significant
7 correlation between the prevalence of IPIs and the length of time since diagnosis. The effect of the
8 chemotherapy sessions on the IPI was also investigated. The cancer patients were grouped
9 according to the planned chemotherapy sessions completed. Group one included participants that
10 completed less than half of the planned session; the second group included participants that had
11 completed half of the planned sessions and the third included participants that had completed more
12 than half of the sessions. The rate of parasitic infection was 9.8%, 22.2% and 8.2% in the first,
13 second and third group, respectively. The difference was statistically significant ($p = 0.02$).

14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
The rate of parasitic infection observed in patients with uterine and ovarian cancer (13.8%),
gastrointestinal cancer (12.4%) and lung cancer (4.8%) was not statistically significant.

4. Discussion

66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

The prevalence of intestinal parasites in chemotherapy patients, hemodialysis patients and the control group was 11.3%, 15%, and 7.3%, respectively. Rasti et al. (2017) reported IPI of 7.6% in cancer patients and 11.9% of IPIs in hemodialysis patients of Kashan, Iran. The main reason for the lower incidence in cancer patients compared with its prevalence in the hemodialysis patients may be because of the short-term effects of the drugs used in chemotherapy (Barazesh et al. 2015). Hemodialysis patients sometimes spend up to 20 years undergoing hemodialysis. Such long-term care increases the risk of contaminations, from parasitic infections including from the health care services (Karadag Tamer and Dervisoglu 2013; Alter et al. 2011). Individuals, who are undergoing

1
2
3
4 dialysis treatments have a high risk of acquiring infections through contact with nursing staff,
5
6 equipment and materials, on surfaces or from hands (Kulik et al. 2008). The prevalence of
7
8 intestinal parasites in the present study is lower than the-prevalence that has been reported among
9
10 immunocompromised and cancer patients in Turkey (43.7%), and Egypt (18%) (Baiomy et al.
11
12 2010; Thom Kleinberg and Roghmann 2013), and hemodialysis patients in Brazil (45.1%) (Kulik
13
14 et al. 2008). The prevalence of parasitic infestation in patients with cancers in India was found to
15
16 be 80%. However, there was not a control group in that study) (Bora et al. 2016). The prevalence
17
18 of IPIs was higher (10–63%) among the patients with different immunosuppressed status
19
20 compared with the control group (Bora et al. 2016; Kulik et al. 2008; Al-Qobati Al-Maktari and
21
22 Derhim 2012; Togeh et al. 2000; Al-Megrin 2010; Ashrafi Tahbaz and Rahmati 2010). The wide
23
24 variation of prevalence may be attributed to the differences in geographical distribution of
25
26 parasites, sanitary practices, and different selection criteria of cases (Bora et al. 2016). In the
27
28 present study, non-pathogenic intestinal protozoan, *B. hominis* was the most prevalent (8.9%)
29
30 parasite observed in immunocompromised patients followed by *E. coli* (1.6%), *I. butschlii* (0.8%),
31
32 *E. nana* (0.6%), *C. mesnili* (0.5%) (Table 2). *B. hominis* was found to be the most common
33
34 intestinal parasite in all studied groups; *G. lamblia* was found once in the control group (Table 2).
35
36 Similar findings have been reported in other studies (Bora et al. 2016; Kulik et al. 2008; Al-Qobati
37
38 Al-Maktari and Derhim 2012; Togeh et al. 2000; Al-Megrin 2010; Ashrafi Tahbaz and Rahmati
39
40 2010; Kazemi et al. 2013). *B. hominis* may act as a pathogen in immunocompromised subjects and
41
42 lead to various types of infections (with or without symptoms). Water, pets, and vegetables are
43
44 probably the main sources of infections. Research indicates that *B. hominis* may be the source of
45
46 such infections (Rao et al.2003; Motta and Silva 2002; Stensvold et al.2007; Abdel-Hameed and
47
48 Hassanin 2011; Iguchi et al. 2009). *B. hominis* and four non-pathogenic protozoans, namely *E.*
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 *coli*, *I. butschlii*, *E. nana*, and *C. mesnili*, had the highest prevalence among the patients and control
5
6 groups (Table 2). *Giardia* and *Cryptosporidium* are two important waterborne parasites
7
8 (Mahmoudi et al. 2013; 2017). In previous studies, *Cryptosporidium* and *Giardia* (oo)cysts were
9
10 detected in surface water samples in Guilan (Mahmoudi et al. 2013; 2015 2017). But, examination
11
12 of stool specimens with formalin ether and Ziehl – Neelsen staining revealed no positive
13
14 *Cryptosporidium* oocyst in either of the three groups (Table 1). Infections by this protozoan have
15
16 been related to poor-quality drinking water (Mahmoudi et al. 2017; Seyrafian et al. 2006; Botero
17
18 et al. 2003; Chieffi et al. 1998), but it cannot be discounted that these patients acquired the parasites
19
20 from contaminated water, despite the fact that in Guilan, water used by nearly 100% of the
21
22 population is subject to quality control. The frequency of *Cryptosporidium* spp. in adult
23
24 hemodialysis patients was reported 4.6% in Brazil (Kulik et al. 2008), 11.5% in Iran (Seyrafian et
25
26 al. 2006), and 20.27% in Turkey (Turkcapar et al. 2002). In addition, in the present study, two
27
28 pathogenic helminths, *S. stercoralis* (0.5%) and *Taenia* species (0.15%) were the only pathogenic
29
30 parasitic helminthes detected in the examined patients. Strongyloidiasis is a soil transmitted
31
32 endemic disease, and most immunocompromised patients are exposed to the infection and its side
33
34 effects, such as diarrhea (Ashrafi Tahbaz and Rahmati 2010).
35
36
37
38
39
40
41
42

43 We observed three cases (0.3%) of infection with this parasite in one hemodialysis and two cancer
44
45 patients. The number of cases observed are lower than the number of cases reported in another
46
47 study in Iran (9.7%) (Sharifdini et al. 2018). Undoubtedly, certain measures, such as not using
48
49 human feces as fertilizer on farms, and health education for farmers could be recommendations
50
51 for the reduction of worm infections and protection of public health. Most cases of infections were
52
53 observed in males rather than females in all three groups, however, they were not statistically
54
55 significant (Table 1). Several studies have suggested that the prevalence of IPIs in males differ
56
57
58
59
60
61
62
63
64
65

1
2
3
4 from females (Al-Qobati Al-Maktari and Derhim 2012; Kia et al. 2008; Sayyari et al. 2005). The
5
6 IPIs were significantly different in relation to the age, where the prevalence rates of IPIs (12.5%)
7
8 in the age group 60–79 years was higher than other age groups. In some similar studies, the highest
9
10 prevalence was reported in the age group above 50 years (Barazesh et al.2015; Monsef et al. 2008).
11
12 No significant relationship was observed between the prevalence of IPIs and gastrointestinal
13
14 symptoms (such as some abdominal pain, diarrhea) (Table 1) and similar observations were
15
16 reported by Naeini et al. (2012). The present research demonstrated no significant association
17
18 between education level and IPIs prevalence (Table 3), which is in line with the finding of Brazesh
19
20 et al. (2015). Nevertheless, several studies observed a significant relationship between education
21
22 level and IPIs prevalence (Naeini et al. 2012; Choy et al. 2014; Daryani et al. 2012). The current
23
24 study demonstrates a significant association between IPIs prevalence and residence (9.6% among
25
26 438 patients living in cities and 18.7% among 203 patients living in rural areas). Omrai et al. (2015)
27
28 found a recognizable relationship between IPIs prevalence and residence but Naeini et al. (2012)
29
30 and Barazesh et al. (2015) found no significant difference between these two variables. The
31
32 differences may be the result of agriculture activities and other effective factors on growth,
33
34 reproduction and transmission of parasites in rural areas as compared with cities (Barazesh et al.
35
36 2015; Naeini et al. 2012; Omrani et al. 2015). We separated hemodialysis participants according
37
38 to length of time receiving the treatment into three categories: 1 – 12 months, 13 – 24 months and
39
40 ≥ 25 months. No significant correlation was observed between IPIs prevalence and hemodialysis
41
42 duration. The association between PDSS (proportion of done sessions of chemotherapy to
43
44 scheduled session) and IPIs prevalence was assessed by allocating the PDSS into three categories
45
46 according to the chemotherapy cycles received: less, intermediate and more than half of
47
48 chemotherapy cycles to scheduled session. Using this classification, we demonstrated that IPIs are
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 more prevalent in members of the second category (more than two other categories) and the
5
6 difference is statistically significant. Chandramathi et al. (2012) used the same categorization and
7
8 demonstrated the higher prevalence of *B. hominis* and *Microsporidium* species in cancer patients
9
10 during the intermediate chemotherapy cycles (Chandramathi et al. 2012). The poisonous effect of
11
12 chemotherapy medicine on the immune system reduces the immune function (Koivusalo and
13
14 Hietanen 2004; Solomayer et al. 2003), thus causing augmentation for the parasitic infection. At
15
16 the end of the therapy course, the anti-oxidant system of patients reacted to the poisonous effects
17
18 of chemotherapy drugs, which may boost their immune system and eventually overcome the
19
20 parasite (Chandramathi et al. 2012). We found 11.9% prevalence rate in cancer patients with
21
22 different types of leukemia with the highest and the lowest rates of IPIs occurring in patients with
23
24 uterine and ovarian cancer (13.8%) and lung cancer (4.8%), respectively (statistically insignificant
25
26 difference). In India, Rudraparta et al. (1997) reported a 16.5% prevalence rate for IPIs in patients
27
28 with gastrointestinal cancer. A prevalence rate of 35.9% in children with leukemia has been
29
30 reported by Zaboli Nejad et al. (2013). The difference may be attributed to methods (direct and
31
32 ELISA) used to diagnose parasitic infection, while we only used the direct method. This study
33
34 revealed the prevalence of parasitic infections was higher in two immunocompromised groups
35
36 (undergoing chemotherapy and hemodialysis) compared with the control group in the study area.
37
38 Detection of intestinal protozoan could be used as indicators of poor hygiene practices (Chieffi et
39
40 al. 1998).
41
42
43
44
45
46
47
48
49
50
51
52

53 **5. Conclusion**

54
55 Most of the observed protozoans in the present study were non-pathogenic. Intestinal pathogenic
56
57 protozoans are transmitted in a similar way to non-pathogenic parasites, infection with pathogenic
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

parasites is always possible in this study area. Given the fact that some endemic parasitic infections such as *S. stercoralis* may be lethal for immunocompromised patients, periodic parasitology examinations are highly recommended for hemodialysis and chemotherapy patients.

Conflicts of interest

We have no conflict of interest regarding this study.

1
2
3
4 **Acknowledgment**
5
6
7
8

9 The authors are very thankful to Vice Chancellor for Research and Technology in Guilan
10 University of Medical Sciences. Also, we are very grateful to the respected staff of the laboratory,
11 hemodialysis and oncology departments of Razi hospital of Rasht, Guilan Oncology Center,
12 Kianmehr Hemodialysis Center and all of those who helped us in conducting and performing this
13
14
15
16
17
18
19 research project.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 **References**
5
6

7 Abdel-Hameed DM, Hassanin OM (2011) Protease activity of *Blastocystis hominis* subtype 3 in
8 symptomatic and asymptomatic patients. *Parasitol Res* 109(2):321-327
9

10
11
12 Al-Megrin W (2010) Patients in Riyadh, Saudi Arabia. *Pakistan J Biol Sci* 13:390-4
13

14
15
16 Al-Qobati SA, Al-Maktari, MT, Derhim M (2012) Intestinal parasitosis among Yemeni patients
17 with cancer, Sana'a, Yemen. *J Egyptian Soc Parasitol* 240:1-8
18
19

20
21
22 Alter M J, Arduino MJ, Lyerla H C, Miller E R, Tokars JI (2001) Recommendations for preventing
23 transmission of infections among chronic hemodialysis patients. *MMWR Recomm Rep* 50 (RR-
24 5):1-43; quiz CE1.
25
26
27

28
29
30 Ashrafi K, Tahbaz A, Rahmati B (2010) *Strongyloides stercoralis*: The most prevalent parasitic
31 cause of eosinophilia in Gilan Province, northern Iran. *Iranian J Parasitol* 5:40
32
33

34
35 Baiomy AMS, Mohamed KAAH, Ghannam MAM, Al- Razek SA (2010) Opportunistic parasitic
36 infections among immunocompromised patients. *J Egypt Soc Parasitol* 40:797-807
37
38

39
40
41 Barazesh A, Fouladvand M, Tahmasebi R, Heydari A, Fallahi J (2015) The prevalence of intestinal
42 parasites in hemodialysis patients in Bushehr, Iran. *Hemodial Internat* 19:447-451
43
44

45
46 Bloom BR, Murray CJ (1992) Tuberculosis: commentary on a reemergent killer. *Sci* 257:1055-
47 1064
48
49

50
51
52 Bora I, Dutta V, Lyngdoh WV, Khyriem AB, Durairaj E, Phukan AC (2016) Study of intestinal
53 parasites among the immunosuppressed patients attending a tertiary-care center in Northeast
54 India. *Int J Med Sci Pub Health* 5:924-29
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 Botero JH, CastañoA, Montoya MN, OcampoNE, Hurtado MI, Lopera MM (2003) A preliminary
5 study of the prevalence of intestinal parasites in immunocompromised patients with and without
6 gastrointestinal manifestations. Revista do Instituto de Medicina Tropical de São Paulo 45:197-
7
8
9
10
11 200

12
13
14
15 Cancer Research UK (2019, May 29) Can parasites cause cancer? Retrieved from
16
17 [https://www.cancerresearchuk.org/about-cancer/causes-of-cancer/infections-eg-hpv-and-](https://www.cancerresearchuk.org/about-cancer/causes-of-cancer/infections-eg-hpv-and-cancer/can-parasites-cause-cancer)
18
19 [cancer/can-parasites-cause-cancer.](https://www.cancerresearchuk.org/about-cancer/causes-of-cancer/infections-eg-hpv-and-cancer/can-parasites-cause-cancer)
20
21

22 Chandramathi S, Suresh K, Anita ZB, Kuppusamy UR (2012) Infections of *Blastocystis hominis*
23 and microsporidia in cancer patients: are they opportunistic? TRSTMH 106:267-269
24
25
26
27

28 Chieffi PP, Sens YA, Paschoalotti MA, Miorin LA, Silva HGC, Jabur P (1998) Infection by
29
30 *Cryptosporidium parvum* in renal patients submitted to renal transplant or hemodialysis. Rev da
31
32 Soc Brasil de Med Trop 31:333-337
33
34
35

36 Choy S H, Al-Mekhlafi HM, Mahdy MA, Nasr NN, Sulaiman M, Lim YA, Surin J (2014)
37
38 Prevalence and associated risk factors of *Giardia* infection among indigenous communities in rural
39
40 Malaysia. Sci Rep 4:6909
41
42
43

44 Cleaveland S, Laurenson MK, Taylor LH (2001) Diseases of humans and their domestic mammals:
45
46 pathogen characteristics, host range and the risk of emergence. Philosophical T Royal Soc London.
47
48 Series B: Biol Sci 356:991-999
49
50
51

52 Daryani A, Sharif M, Nasrolahei M, Khalilian A, Mohammadi A, Barzegar G (2012)
53
54 Epidemiological survey of the prevalence of intestinal parasites among schoolchildren in Sari,
55
56 northern Iran. TRSTMH 106: 455-459
57
58
59
60
61
62
63
64
65

1
2
3
4 De Martel C, Georges D, Bray F, Ferlay J, Clifford GM (2020) Global burden of cancer attributable
5 to infections in 2018: a worldwide incidence analysis. *Lancet Global Health* 8:e180-e190
6
7

8
9
10 Ferreira MS Borges AS (2002) Some aspects of protozoan infections in immunocompromised
11 patients: a review. *Memorias do Instituto Oswaldo Cruz* 97:443-457
12
13

14
15 Garcia LS (2007) *Diagnostic Medical Parasitology*. 5th Edition, Asm Press, Washington Dc, 850-
16
17
18 858
19

20
21 Garcia LS, Bruckner DA, Brewer TC, Shimizu RY (1983) Techniques for the recovery and
22 identification of *Cryptosporidium* oocysts from stool specimens. *J Clin Microbiol* 18:185-190
23
24

25
26 Iguchi A, Yoshikawa H, Yamada M, Kimata I, Arizono N (2009) Expression of interferon gamma
27 and pro-inflammatory cytokines in the cecal mucosa of rats experimentally infected with
28
29
30
31 *Blastocystis* sp. strain RN94-9. *Parasitol Res* 105:135
32

33
34 Karadag G, Tamer GS, Dervisoglu E (2013) Investigation of intestinal parasites in dialysis
35 patients. *Saudi Med J* 34:714-8
36
37

38
39
40 Koivusalo R, Hietanen S (2004) The cytotoxicity of chemotherapy drugs varies in cervical cancer
41 cells depending on the p53 status. *Cancer Biol Therapy* 3:1177-1183
42
43

44
45 Kazemi E, Tavalla M, Maraghi S, Yad MJ, Latifi M (2016) Frequency of microsporidial infection
46 in immunocompromised patients with staining and molecular methods based on internal
47 transcribed spacer region gene in two cities of southwest Iran during 2013-2014. *Asian J Pharm*
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

1
2
3
4 Kia EB, Hosseini M, Nilforoushan MR, Meamar AR, Rezaeian M (2008) Study of intestinal
5
6 protozoan parasites in rural inhabitants of Mazandaran province, Northern Iran. Iran. J Parasitol
7
8 12:21-25
9

10
11
12 Kulik RA, Falavigna DLM, NishiL Araujo SM (2008) *Blastocystis* sp. and other intestinal
13
14 parasites in hemodialysis patients. Brazil. J Inf Dis 12:338-341
15
16

17
18 Mahmoudi MR, Kazemi B, Mohammadiha A, Mirzaei A, Karanis P (2013) Detection of
19
20 *Cryptosporidium* and *Giardia* (oo)cysts by IFA, PCR and LAMP in surface water from Rasht,
21
22 Iran. TRSTMH 107: 511-517
23
24

25
26 Mahmoudi MR, Nazemalhosseini-Mojarad E, Kazemi B, Haghghi A, MirzaeiA, Mohammadiha
27
28 A, Karanis P (2015) *Cryptosporidium* genotypes and subtypes distribution in river water in Iran. J
29
30 Wat Health 13:600-606
31
32

33
34 Mahmoudi MR, Ongerth JE, Karanis P (2017) *Cryptosporidium* and cryptosporidiosis: the Asian
35
36 perspective. Int J Hyg Environ Health 220:1098-1109
37
38

39
40 Monsef AR, Hashemi SH, Abbasi M, Taherkhani H, Shalchi Z, Eliasi A (2007) Frequency of
41
42 intestinal parasites in patients with malignancy, admitted in oncology ward of Sina Hospital,
43
44 Hamadan, Iran. J Gorgan Univ Med Sci 9:51-55
45
46

47
48 Motta MEFA, Silva GAP (2002) Parasites induced diarrheas. Rev Bras Saúde Matern
49
50 Infant 2:117-127
51
52

53
54 Naeini AE, Sharifi M, Shahidi S, Taheri S, Seirafian S, Taheri D, Harandi AA (2012) Intestinal
55
56 fungal and parasitic infections in kidney transplant recipients: a multi-center study. Saudi J Kidney
57
58 Dis Transplant 23:677
59
60
61
62
63
64
65

1
2
3
4 Omrani VF, Fallahi S, Rostami A, Siyadatpanah A, Barzgarpour G, Mehravar S, Joneidi Z (2015)
5
6 Prevalence of intestinal parasite infections and associated clinical symptoms among patients with
7
8 end-stage renal disease undergoing hemodialysis. *Inf* 43:537-544
9
10
11
12 Rao K, Sekar U, Iraivan KT, Abraham G, Soundararajan P (2003) *Blastocystis hominis*—an
13
14 emerging cause of diarrhoea in renal transplant recipients. *J Assoc Physicians India* 51:719-21
15
16
17
18 Rasti S, Hassanzadeh M, Hooshyar H, Momen-Heravi M, Mousavi SGA, Abdoli A (2017)
19
20 Intestinal parasitic infections in different groups of immunocompromised patients in Kashan and
21
22 Qom cities, central Iran. *Scandin J Gastroenterol* 52:738-741
23
24
25
26 Rudrapatna JS, KumarV, Sridhar H (1997) Intestinal parasitic infections in patients with
27
28 malignancy. *J Diarrhoeal Dis Res* 15:71-74.
29
30
31
32 Samaras V, Petros I, Rafailidis PI, Mourtzoukou EG, Peppas G, Falagas ME (2010) Chronic
33
34 bacterial and parasitic infections and cancer: a review. *J Infect Dev Ctries* 4:267-281
35
36
37 Sayyari AA, Imanzadeh F, Bagheri Yazdi SA, Karami H, Yaghoobi M (2005) Prevalence of
38
39 intestinal parasitic infections in the Islamic Republic of Iran. *Int J Infect Control* 4:e15593
40
41
42
43 Seyrafian S, Pestehchian N, Kerdegari M, Yousefi HA, Bastani B (2006) Prevalence rate of
44
45 *Cryptosporidium* infection in hemodialysis patients in Iran. *Hemodial Int* 10: 375-379
46
47
48
49 Sharifdini M, Keyhani A, Eshraghian MR, Kia EB (2018) Molecular diagnosis of strongyloidiasis
50
51 in a population of an endemic area through nested-PCR. *Gastroenterol Hepatol Bed Bench* 11:68
52
53
54
55 Solomayer EF, Feuerer M, Bai L, Umansky V, Beckhove P, Meyberg GC, Diel IJ (2003) Influence
56
57 of adjuvant hormone therapy and chemotherapy on the immune system analysed in the bone
58
59 marrow of patients with breast cancer. *Clin Cancer Res* 9:174-180
60
61
62
63
64
65

1
2
3
4 Stensvold CR, Suresh GK, Tan KS, Thompson RA, Traub RJ, Viscogliosi E, Clark CG(2007)
5
6 Terminology for *Blastocystis* subtypes—a consensus. Trends Parasitol 23:93-96
7
8

9
10 Thom KA, Kleinberg M, Roghmann MC (2013) Infection prevention in the cancer center. Clin Inf
11
12 Dis 57:579-585
13
14

15 Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, Garg AX (2006) Chronic kidney
16
17 disease and mortality risk: a systematic review. J Am Soc Nephrol 17: 2034-2047
18
19

20
21 Togeh GR, Keihani M, Athari A, Sadafi H (2000) Parasitic infestation in cancer patients
22
23 chemotherapy. Tehran University Medical Journal TUMS Publications 58:52-58
24
25

26 Turkcapar N, Kutlay S, Nergizoglu G, Atli T, Duman N (2002) Prevalence of *Cryptosporidium*
27
28 infection in hemodialysis patients. Nephron 90:344-346
29
30

31
32 World Health Organisation (2020). Cancer retrieved from [https://www.who.int/news-room/fact-](https://www.who.int/news-room/fact-sheets/detail/cancer)
33
34 sheets/detail/cancer.
35
36

37 Zabolinejad N, Berenji F, Eshkaftaki EB, Badeii Z, Banihashem A, Afzalaqaei M (2013) Intestinal
38
39 parasites in children with lymphohematopoietic malignancy in Iran, Mashhad. Jundishapur J
40
41 Microbiol 6: e7765
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Table1: Demographic characteristics of Immunocompromised patients and Control group.

	Hemodialys N=279 N (%)	Cancer N=362 N (%)	Control N=399 N (%)	Total N=1040 N (%)
Variable				
Age group				
≤30	12 (4.3%)	17 (4.7%)	19 (4.8%)	48 (4.6%)
31-59	53 (19%)	108 (29.8%)	110 (27.6%)	271 (26.05%)
60-79	164 (58.8%)	188 (51.9%)	202 (50.6%)	554 (53.3%)
≥80	50 (17.9%)	49 (13.5%)	68 (17%)	167 (16.05%)
Sex				
male	160 (57.3%)	171 (47.2%)	190 (47.6%)	521 (50.1%)
female	119 (42.7%)	191 (52.8%)	209 (52.4%)	519 (49.9%)
Educational level				
Primary school	214 (76.7%)	277 (76.5%)	235 (58.9%)	726 (69.8%)
High school	48 (17.2%)	61 (16.9%)	129 (32.33%)	238 (22.9%)
University	17 (6.1%)	24 (6.6%)	35 (8.77%)	76 (3.36%)
Location				
city	207 (74.2%)	131 (36.2%)	248 (62.1%)	586 (56.3%)
village	72 (25.8%)	231 (63.8%)	151 (37.8%)	454 (43.6%)
Symptoms				
No	235 (84.2%)	284 (78.5%)	358 (89.7%)	877 (84.3%)
Yes	44 (15.8%)	78 (21.5%)	41 (10.3%)	163 (15.7%)

Table 2: Prevalence of Intestinal parasitic infections and infection rate among immunocompromised and Control groups.

Parasite	Hemodialysis N (%)	Chemotherapy N (%)	Total of immunocompromised N (%)	Control N (%)	<i>P</i> value
<i>Blastocystis hominis</i>	28 (10.1%)	29 (8%)	57 (8.9%)	16 (4%)	
<i>Entamoeba coli</i>	7 (2.5%)	3 (0.8%)	10 (1.6%)	1 (0.25%)	
<i>Endolimax nana</i>	2 (0.7%)	2 (0.6%)	4 (0.6%)	1 (0.25%)	
<i>Iodamoeba butschlii</i>	2 (0.7%)	3 (0.8%)	5 (0.8%)	2 (0.5%)	
<i>Chilomastix mesnili</i>	2 (0.7%)	1 (0.3%)	3 (0.5%)	1 (0.25%)	
<i>Giardia lamblia</i>	0 (0%)	0 (0%)	0 (0%)	8 (2%)	
<i>Cryptosporidium spp.</i>	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
<i>Strongyloides stercoralis</i>	1 (0.36%)	2 (0.55%)	3 (0.5%)	0 (0%)	
<i>Taenia spp.</i>	0 (0%)	1 (0.28%)	1 (0.15)	0 (0%)	
Infected	42 (15%)	41 (11.3%)	83 (13%)	29 (7.3%)	0.008
Non-infected	237 (85%)	321 (88.7%)	558 (87%)	370 (92.7%)	

Table 3: Demographic characteristics according to the existence or absence of parasites in immunocompromised patients.

		Parasitized (108) N (%)	Non-parasitized (932) N (%)	Total (1040) N (%)	<i>P</i> value
Variable					
<hr/>					
Age group					
	≤30	6 (12.5%)	42 (87.5%)	48 (100%)	0.43
	31-59	26 (9.6%)	245 (90.4%)	271 (100%)	
	60-79	64 (11.6%)	490 (88.4)	554 (100%)	
	≥80	12 (7.2%)	155 (92.8%)	167 (100%)	
Sex					
	male	56 (10.7%)	465 (89.3%)	521 (100%)	0.78
	female	52 (10.2%)	467 (89.8%)	519 (100%)	
Educational level					
	Primary school	81 (11.1%)	645 (88.9%)	726 (100%)	0.87
	High school	18 (7.6%)	220 (92.4%)	238 (100%)	
	University	9 (11.8%)	67 (88.2%)	76 (100%)	
Location					
	urban	45 (7.7%)	541 (92.3%)	586 (100%)	0.001
	rural	63 (13.9%)	391 (86.1%)	454 (100%)	
Symptoms					
	No	76 (8.7%)	801 (91.3%)	877 (100%)	0.001
	Yes	32 (19.6%)	131 (80.4%)	163 (100%)	